Trasylol (aprotinin injection) is used for prophylactic use to reduce blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion. On November 5, 2007 The U.S. Food and Drug Administration announced that Bayer Pharmaceuticals (the makers of Trasylol) agreed to the FDA- requested suspension of Trasylol. Trasylol was recalled because heart bypass, heart valve replacement and other cardiac surgery patients who received Trasylol were more likely to die. The deaths were due to:
• kidney failure
• heart failure
• heart attacks
• and strokes the patients suffered following the surgery.
———
About Nachawati Law Group
Nachawati Law Group represents parties in mass tort litigation, businesses and governmental entities in contingent litigation, and individuals in complex personal injury litigation. For more information, visit contact or call 214-890-0711.
